Kiniksa Pharmaceuticals International, plc is a biopharmaceutical company focused on discovering, acquiring, developing and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Its portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. Its ARCALYST is used for the treatment of recurrent pericarditis and reduces the risk of recurrence in adults and children 12 years and older. ARCALYST is also approved for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome, and the maintenance of remission in Deficiency of Interleukin-1 Receptor Antagonist. Its other portfolio includes KPL-387, KPL-1161, Abiprubart, and Mavrilimumab. Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha.
高成長
同社の収益は過去3年間にわたり着実に増加しており、年平均で150.71%の成長率を示しています。
高い利益成長
同社の純利益は業界をリードしており、最新の年間純利益はUSD 677.56Mです。
黒字転換
同社は黒字転換を果たし、最新の年間純利益はUSD です。
適正水準
同社の最新のPEは61.15で、過去3年間の水準と比較して適正圏にあります。
機関投資家の買い増し
最新の機関投資家の保有株数は51.67M株で、前四半期比で4.10%増加しています。
ジョン・ハスマンが保有
スター投資家ジョン・ハスマンは本銘柄を19.48K株保有しています。